JAK-STAT-mediated chronic inflammation impairs cytotoxic T lymphocyte activation to decrease anti-PD-1 immunotherapy efficacy in pancreatic cancer
出版年份 2017 全文链接
标题
JAK-STAT-mediated chronic inflammation impairs cytotoxic T lymphocyte activation to decrease anti-PD-1 immunotherapy efficacy in pancreatic cancer
作者
关键词
-
出版物
OncoImmunology
Volume 6, Issue 3, Pages e1291106
出版商
Informa UK Limited
发表日期
2017-02-11
DOI
10.1080/2162402x.2017.1291106
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Immunologic and Metabolic Features of Pancreatic Ductal Adenocarcinoma Define Prognostic Subtypes of Disease
- (2016) J. Hutcheson et al. CLINICAL CANCER RESEARCH
- Augmented efficacy of brentuximab vedotin combined with ruxolitinib and/or Navitoclax in a murine model of human Hodgkin’s lymphoma
- (2016) Wei Ju et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The C-reactive Protein to Albumin Ratio Predicts Long-Term Outcomes in Patients with Pancreatic Cancer After Pancreatic Resection
- (2016) Koichiro Haruki et al. WORLD JOURNAL OF SURGERY
- Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints
- (2016) Shohei Koyama et al. Nature Communications
- Transformation of the tumour microenvironment by a CD40 agonist antibody correlates with improved responses to PD-L1 blockade in a mouse orthotopic pancreatic tumour model
- (2016) Nadia M. Luheshi et al. Oncotarget
- STAT3 inhibition for cancer therapy: Cell-autonomous effects only?
- (2016) Guido Kroemer et al. OncoImmunology
- Efficacy of JAK/STAT pathway inhibition in murine xenograft models of early T-cell precursor (ETP) acute lymphoblastic leukemia
- (2015) S. L. Maude et al. BLOOD
- IFN-γ from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer
- (2015) K Abiko et al. BRITISH JOURNAL OF CANCER
- Targeting the Inactive Conformation of JAK2 in Hematological Malignancies
- (2015) Olli Silvennoinen et al. CANCER CELL
- Convergent Mutations and Kinase Fusions Lead to Oncogenic STAT3 Activation in Anaplastic Large Cell Lymphoma
- (2015) Ramona Crescenzo et al. CANCER CELL
- STAT3 Inhibition Enhances the Therapeutic Efficacy of Immunogenic Chemotherapy by Stimulating Type 1 Interferon Production by Cancer Cells
- (2015) Heng Yang et al. CANCER RESEARCH
- Asymmetric Action of STAT Transcription Factors Drives Transcriptional Outputs and Cytokine Specificity
- (2015) Kiyoshi Hirahara et al. IMMUNITY
- Distinct Acute Lymphoblastic Leukemia (ALL)-associated Janus Kinase 3 (JAK3) Mutants Exhibit Different Cytokine-Receptor Requirements and JAK Inhibitor Specificities
- (2015) Elisabeth Losdyck et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Anti–PD-1/PD-L1 therapy of human cancer: past, present, and future
- (2015) Lieping Chen et al. JOURNAL OF CLINICAL INVESTIGATION
- Randomized, Double-Blind, Phase II Study of Ruxolitinib or Placebo in Combination With Capecitabine in Patients With Metastatic Pancreatic Cancer for Whom Therapy With Gemcitabine Has Failed
- (2015) Herbert I. Hurwitz et al. JOURNAL OF CLINICAL ONCOLOGY
- Type I/II cytokines, JAKs and new strategies for treating autoimmune diseases
- (2015) Daniella M. Schwartz et al. Nature Reviews Rheumatology
- Selective targeting of JAK/STAT signaling is potentiated by Bcl-xL blockade in IL-2–dependent adult T-cell leukemia
- (2015) Meili Zhang et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Opposing roles of STAT1 and STAT3 in IL-21 function in CD4+T cells
- (2015) Chi-Keung Wan et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- AZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung cancer
- (2015) David Hong et al. Science Translational Medicine
- Vesicular stomatitis virus expressing interferon-β is oncolytic and promotes antitumor immune responses in a syngeneic murine model of non-small cell lung cancer
- (2015) Manish R. Patel et al. Oncotarget
- Angiogenic gene signature in human pancreatic cancer correlates with TGF-beta and inflammatory transcriptomes
- (2015) Kelly E. Craven et al. Oncotarget
- Activating JAK1 mutation may predict the sensitivity of JAK-STAT inhibition in hepatocellular carcinoma
- (2015) Shuqun Yang et al. Oncotarget
- TCGA data and patient-derived orthotopic xenografts highlight pancreatic cancer-associated angiogenesis
- (2015) Jesse Gore et al. Oncotarget
- Development of an Automated PD-L1 Immunohistochemistry (IHC) Assay for Non–Small Cell Lung Cancer
- (2015) Therese Phillips et al. APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY
- Editorial: Decernotinib: A Next-Generation Jakinib
- (2015) Massimo Gadina et al. Arthritis & Rheumatology
- Induction of T-cell Immunity Overcomes Complete Resistance to PD-1 and CTLA-4 Blockade and Improves Survival in Pancreatic Carcinoma
- (2015) R. Winograd et al. Cancer Immunology Research
- IFN Induces DNA Methylation-Silenced GPR109A Expression via pSTAT1/p300 and H3K18 Acetylation in Colon Cancer
- (2015) K. Bardhan et al. Cancer Immunology Research
- Interferon-γ-induced activation of JAK1 and JAK2 suppresses tumor cell susceptibility to NK cells through upregulation of PD-L1 expression
- (2015) Roberto Bellucci et al. OncoImmunology
- Activity of therapeutic JAK 1/2 blockade in graft-versus-host disease
- (2014) S. Spoerl et al. BLOOD
- Mechanisms of Jak/STAT Signaling in Immunity and Disease
- (2014) Alejandro V. Villarino et al. JOURNAL OF IMMUNOLOGY
- Cancer-related inflammation and treatment effectiveness
- (2014) Connie I Diakos et al. LANCET ONCOLOGY
- Interleukin-21: a double-edged sword with therapeutic potential
- (2014) Rosanne Spolski et al. NATURE REVIEWS DRUG DISCOVERY
- Interferons and Their Stimulated Genes in the Tumor Microenvironment
- (2014) HyeonJoo Cheon et al. SEMINARS IN ONCOLOGY
- Second-line treatment in advanced pancreatic cancer: a comprehensive analysis of published clinical trials
- (2013) O. E. Rahma et al. ANNALS OF ONCOLOGY
- The JAK-inhibitor ruxolitinib impairs dendritic cell function in vitro and in vivo
- (2013) A. Heine et al. BLOOD
- Molecular Pathways: JAK/STAT Pathway: Mutations, Inhibitors, and Resistance
- (2013) A. Quintas-Cardama et al. CLINICAL CANCER RESEARCH
- IL-21 Promotes CD8+ CTL Activity via the Transcription Factor T-bet
- (2013) A. P. R. Sutherland et al. JOURNAL OF IMMUNOLOGY
- STAT3 Regulates Proliferation and Survival of CD8+T Cells: Enhances Effector Responses to HSV-1 Infection, and Inhibits IL-10+Regulatory CD8+T Cells in Autoimmune Uveitis
- (2013) Cheng-Rong Yu et al. MEDIATORS OF INFLAMMATION
- The microRNA miR-155 controls CD8+ T cell responses by regulating interferon signaling
- (2013) Donald T Gracias et al. NATURE IMMUNOLOGY
- Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
- (2013) Daniel D. Von Hoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- The immune network in pancreatic cancer development and progression
- (2013) S M Wörmann et al. ONCOGENE
- Up-Regulation of PD-L1, IDO, and Tregs in the Melanoma Tumor Microenvironment Is Driven by CD8+ T Cells
- (2013) S. Spranger et al. Science Translational Medicine
- Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors
- (2013) E. A. Akbay et al. Cancer Discovery
- Pancreatic adenocarcinoma: ESMO-ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2012) T. Seufferlein et al. ANNALS OF ONCOLOGY
- IFN R signaling mediates alloreactive T-cell trafficking and GVHD
- (2012) J. Choi et al. BLOOD
- JAK2/STAT5 Inhibition Circumvents Resistance to PI3K/mTOR Blockade: A Rationale for Cotargeting These Pathways in Metastatic Breast Cancer
- (2012) Adrian Britschgi et al. CANCER CELL
- Genomic Sequencing of Key Genes in Mouse Pancreatic Cancer Cells
- (2012) Y. Wang et al. CURRENT MOLECULAR MEDICINE
- The JAK-STAT Pathway at Twenty
- (2012) George R. Stark et al. IMMUNITY
- Robust tumor immunity to melanoma mediated by interleukin-9–producing T cells
- (2012) Rahul Purwar et al. NATURE MEDICINE
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
- (2012) Julie R. Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Modulation of Activation-Loop Phosphorylation by JAK Inhibitors Is Binding Mode Dependent
- (2012) Rita Andraos et al. Cancer Discovery
- Involvement of STAT3 in immune evasion during lung tumorigenesis
- (2012) Hiroshi Kida et al. OncoImmunology
- A Prospective Comparison of the Prognostic Value of Tumor- and Patient-Related Factors in Patients Undergoing Potentially Curative Surgery for Pancreatic Ductal Adenocarcinoma
- (2011) Nigel B. Jamieson et al. ANNALS OF SURGICAL ONCOLOGY
- Stat3 and MMP7 Contribute to Pancreatic Ductal Adenocarcinoma Initiation and Progression
- (2011) Akihisa Fukuda et al. CANCER CELL
- Stat3/Socs3 Activation by IL-6 Transsignaling Promotes Progression of Pancreatic Intraepithelial Neoplasia and Development of Pancreatic Cancer
- (2011) Marina Lesina et al. CANCER CELL
- STAT3 Plays a Critical Role in KRAS-Induced Pancreatic Tumorigenesis
- (2011) R. B. Corcoran et al. CANCER RESEARCH
- Selective Inhibition of JAK1 and JAK2 Is Efficacious in Rodent Models of Arthritis: Preclinical Characterization of INCB028050
- (2010) J. S. Fridman et al. JOURNAL OF IMMUNOLOGY
- Janus kinases in immune cell signaling
- (2009) Kamran Ghoreschi et al. IMMUNOLOGICAL REVIEWS
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started